Patents by Inventor Max J. Paape

Max J. Paape has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7361351
    Abstract: Studies in mice and humans indicate that membrane CD14 (mCD14) on the cell surface of monocytes, macrophages, and PMN mediates the activation of these cells by LPS. The soluble CD14 (sCD14) present in the circulation also binds to LPS and blocks LPS binding to mCD14. To determine the role of a recombinant bovine soluble CD14 polypeptide in cellular activation by LPS, a recombinant bovine soluble CD14 polypeptide, rbosCD14, was cloned and expressed in a baculovirus expression system. Results indicated that rbosCD14 inhibited the LPS-induced increase in CD18 expression and TNF? mRNA in vitro and reduced mortality in mice injected with LPS. Further, rbosCD14 sensitized mammary epithelial cells to low concentrations of LPS resulting in recruitment of white blood cells and prevention of LPS-induced infection.
    Type: Grant
    Filed: June 6, 2005
    Date of Patent: April 22, 2008
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Yan Wang, Dante S. Zarlenga, Max J. Paape
  • Patent number: 7332592
    Abstract: Studies in mice and humans indicate that membrane CD14 (mCD14) on the cell surface of monocytes, macrophages, and PMN mediates the activation of these cells by LPS. The soluble CD14 (sCD14) present in the circulation also binds to LPS and blocks LPS binding to mCD14. To determine the role of a recombinant bovine soluble CD14 polypeptide in cellular activation by LPS, a recombinant bovine soluble CD14 polypeptide, rbosCD14, was cloned and expressed in a baculovirus expression system. Results indicated that rbosCD14 inhibited the LPS-induced increase in CD18 expression and TNF? mRNA in vitro and reduced mortality in mice injected with LPS. Further, rbosCD14 sensitized mammary epithelial cells to low concentrations of LPS resulting in recruitment of white blood cells and prevention of LPS-induced infection.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: February 19, 2008
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Yan Wang, Dante S. Zarlenga, Max J. Paape
  • Patent number: 7045510
    Abstract: A method of preventing or treating mastitis in a mammal, involving administering to the mammal a therapeutically effective amount of diethylaminoethyl-dextran (DEAE-dextran) or dextran.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: May 16, 2006
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventor: Max J. Paape
  • Patent number: 6984503
    Abstract: Studies in mice and humans indicate that membrane CD14 (mCD14) on the cell surface of monocytes, macrophages, and PMN mediates the activation of these cells by LPS. The soluble CD14 (sCD14) present in the circulation also binds to LPS and blocks LPS binding to mCD14. To determine the role of a recombinant bovine soluble CD14 polypeptide in cellular activation by LPS, a recombinant bovine soluble CD14 polypeptide, rbosCD14, was cloned and expressed in a baculovirus expression system. Results indicated that rbosCD14 inhibited the LPS-induced increase in CD18 expression and TNF? mRNA in vitro and reduced mortality in mice injected with LPS. Further, rbosCD14 sensitized mammary epithelial cells to low concentrations of LPS resulting in recruitment of white blood cells and prevention of LPS-induced infection.
    Type: Grant
    Filed: June 27, 2002
    Date of Patent: January 10, 2006
    Assignee: The United States of America as represented by the Secretary of the Agriculture
    Inventors: Yan Wang, Dante S. Zarlenga, Max J. Paape